>
Starpharma Holdings logo

SPL - Starpharma Holdings Share Price

A$1.85 -0.0  -0.3%

Last Trade - 2:37am

Sector
Healthcare
Size
Mid Cap
Market Cap £421.1m
Enterprise Value £382.7m
Revenue £1.53m
Position in Universe 335th / 1898
Bullish
Bearish
Unlock SPL Revenue
Momentum
Relative Strength (%)
1m -12.8%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -26.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
194.9
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
1.70 4.57 3.65 4.96 2.72 7.12 14.8 33.0 +33.2%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020,Starpharma Holdings Limited revenues decreased 77% toA$1.3M. Net loss increased 78% to A$10.4M. Revenues reflectRoyalty, Customer & License revenue decrease of 91% toA$486K, Interest Revenue decrease of 52% to A$152K. Highernet loss reflects Corporate, administration and financeincrease of 61% to A$2.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

SPL Revenue Unlock SPL Revenue

Net Income

SPL Net Income Unlock SPL Revenue

Normalised EPS

SPL Normalised EPS Unlock SPL Revenue

PE Ratio Range

SPL PE Ratio Range Unlock SPL Revenue

Dividend Yield Range

SPL Dividend Yield Range Unlock SPL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
SPL EPS Forecasts Unlock SPL Revenue
Profile Summary

Starpharma Holdings Limited is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The Company utilizes dendrimers, which is a type of synthetic nanoscale polymer that is regular in size and structure and suited to pharmaceutical and medical uses. The Company’s development programs, including VivaGel portfolio and DEP drug delivery. The Company’s DEP drug delivery, which includes DEP docetaxel, DEP cabazitaxel, DEP irinotecan and Targeted-DEP. It develops and commercializes dendrimer nanotechnology across various applications, including sexual health, drug delivery for pharmaceuticals, animal health, coatings and inks, crop protection, diagnostics and research reagents, cosmetics and water treatment. Its products are based on VivaGel (SPL7013, astodrimer sodium), a dendrimer, which has antimicrobial properties. It has both partnered and internal programs in drug delivery.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated May 13, 1997
Public Since September 28, 2000
No. of Shareholders: 6,915
No. of Employees: 49
Sector Healthcare
Industry Pharmaceuticals
Index S&P/ASX All Ordinaries , S&P/ASX 300 , ASX Small Ordinaries ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 406,015,212
Free Float (0.0%)
Eligible for
ISAs
SIPPs
SPL Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for SPL
Upcoming Events for SPL
Frequently Asked Questions for Starpharma Holdings
What is the Starpharma Holdings share price?

As of 2:37am, shares in Starpharma Holdings are trading at A$1.85, giving the company a market capitalisation of £421.1m. This share price information is delayed by 15 minutes.

How has the Starpharma Holdings share price performed this year?

Shares in Starpharma Holdings are currently trading at A$1.85 and the price has moved by 65.63% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Starpharma Holdings price has moved by 22.38% over the past year.

What are the analyst and broker recommendations for Starpharma Holdings?

Of the analysts with advisory recommendations for Starpharma Holdings, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Starpharma Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Starpharma Holdings next release its financial results?

Starpharma Holdings is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Starpharma Holdings dividend yield?

Starpharma Holdings does not currently pay a dividend.

Does Starpharma Holdings pay a dividend?

Starpharma Holdings does not currently pay a dividend.

When does Starpharma Holdings next pay dividends?

Starpharma Holdings does not currently pay a dividend.

How do I buy Starpharma Holdings shares?

To buy shares in Starpharma Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Starpharma Holdings?

Shares in Starpharma Holdings are currently trading at A$1.85, giving the company a market capitalisation of £421.1m.

Where are Starpharma Holdings shares listed? Where are Starpharma Holdings shares listed?

Here are the trading details for Starpharma Holdings:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: SPL
What kind of share is Starpharma Holdings?

Based on an overall assessment of its quality, value and momentum, Starpharma Holdings is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Starpharma Holdings share price forecast 2021?

Shares in Starpharma Holdings are currently priced at A$1.85. At that level they are trading at 9.16% discount to the analyst consensus target price of 0.00.

Analysts covering Starpharma Holdings currently have a consensus Earnings Per Share (EPS) forecast of -0.025 for the next financial year.

How can I tell whether the Starpharma Holdings share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Starpharma Holdings. Over the past six months, the relative strength of its shares against the market has been 10.26%. At the current price of A$1.85, shares in Starpharma Holdings are trading at 19.54% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Starpharma Holdings PE Ratio?

We were not able to find PE ratio data for Starpharma Holdings.

Who are the key directors of Starpharma Holdings?

Starpharma Holdings's management team is headed by:

Jeremy Paull - VPR
Jacinth Fairley - CEO
Nigel Baade - CFO
David Owen - VPR
Zita Peach - NID
Peter Turvey - NVC
A Tony Eglezos - VBD
Robert Thomas - NEC
David McIntyre - NID
Who are the major shareholders of Starpharma Holdings?

Here are the top five shareholders of Starpharma Holdings based on the size of their shareholding:

Allan Gray Australia Pty Ltd Investment Advisor
Percentage owned: 10.74% (43.6m shares)
M&G Global Themes Fund Mutual Fund
Percentage owned: 7.92% (32.2m shares)
Allianz Global Investors Asia Pacific Limited Investment Advisor/Hedge Fund
Percentage owned: 7.91% (32.1m shares)
M & G Investment Management Ltd. Investment Advisor
Percentage owned: 7.85% (31.9m shares)
Allianz Oriental Income Fund Mutual Fund
Percentage owned: 4.95% (20.1m shares)
Similar to SPL
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.